SCHEMBL2815966

SCHEMBL2815966

Cc1nc[nH]c1C[C@H](N)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.49
CYP3A4 P08684 1/20 0.49
ALPI P09923 1/20 0.44
PKM P14618 1/20 0.44
PTGS1 P23219 1/20 0.44
XIAP P98170 1/20 0.44
GRIA1 P42261 7/20 0.43
GRIA3 P42263 7/20 0.43
GRIA2 P42262 6/20 0.43
GRIA4 P48058 6/20 0.43
MAPT P10636 3/20 0.40
GRIK1 P39086 3/20 0.40
GRIK5 Q16478 3/20 0.40
MEN1 O00255 2/20 0.40
TSHR P16473 2/20 0.40
KMT2A Q03164 2/20 0.40
GRIK2 Q13002 2/20 0.40
GRIK3 Q13003 2/20 0.40
GRIK4 Q16099 2/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5285204 1.00 SLC7A5 (0.49) SLC7A5CYP3A4ALPIPKMPTGS1
SCHEMBL22070454 0.83 CYP3A4 (0.32) SLC7A5CYP3A4CYP2C19HSD17B10
SCHEMBL5795469 0.81 SLC7A5 (0.46) SLC7A5CYP3A4ALPIPKMPTGS1
SCHEMBL8701275 0.80 SLC7A5 (0.49) SLC7A5CYP3A4ALPIPKMPTGS1
SCHEMBL17308615 0.80 SLC7A5 (0.49) SLC7A5CYP3A4ALPIPKMPTGS1
SCHEMBL5280033 0.80 SLC7A5 (0.49) SLC7A5CYP3A4ALPIPKMPTGS1
SCHEMBL28170277 0.80 SLC7A5 (0.49) SLC7A5CYP3A4ALPIPKMPTGS1
SCHEMBL17293244 0.80 SLC7A5 (0.49) SLC7A5CYP3A4ALPIPKMPTGS1
SCHEMBL17292898 0.80 SLC7A5 (0.49) SLC7A5CYP3A4ALPIPKMPTGS1
SCHEMBL17308685 0.79 SLC7A5 (0.47) SLC7A5CYP3A4ALPIPKMPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12565517-B2 Cyclic peptide having CTLA-4 inhibitory activity and use thereof GENEFRONTIER CORPORATION (JP) 2026-03-03 US disclosed
WO-2026040002-A1 COMPOSITION AND METHOD FOR CARING FOR THE SKIN L'OREAL (FR) 2026-02-26 WO disclosed
US-20240092836-A1 CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF GENEFRONTIER CORPORATION (JP) 2024-03-21 US disclosed
CN-114599389-A Variant FC domains and uses thereof 奇达拉治疗公司 2022-06-07 CN disclosed
US-20100249042-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS PROCYTE CORPORATION (US) 2010-09-30 US disclosed
EP-1613302-B1 PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO PROCYTE CORP (US) 2009-12-23 EP disclosed
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN PROCYTE CORPORATION (US) 2008-10-16 US disclosed
US-7384916-B2 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2008-06-10 US disclosed
EP-1866036-A2 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN PROCYTE CORPORATION (US) 2007-12-19 EP disclosed
EP-1765280-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING HYPERPIGMENTATION OF SKIN PROCYTE CORPORATION (US) 2007-03-28 EP disclosed
US-20040214749-A1 Compositions and methods for treatment of psoriasis PROCYTE CORPORATION (US) 2004-10-28 US disclosed
WO-2004087740-A2 PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO PROCYTE CORPORATION (US) 2004-10-14 WO disclosed
US-20040198639-A1 Preserved and stable compositions containing peptide copper complexes and methods related thereto PROCYTE CORPORATION 2004-10-07 US disclosed
US-20040142853-A1 Stimulation of hair growth by compositions containing peptide copper complexes and minoxidil PROCYTE CORPORATION 2004-07-22 US disclosed
WO-2004043415-A1 STIMULATION OF HAIR GROWTH BY COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND MINOXIDIL PROCYTE CORPORATION (US) 2004-05-27 WO disclosed
EP-0765152-B1 STIMULATION OF HAIR GROWTH BY PEPTIDE-COPPER COMPLEXES PROCYTE CORP (US) 2001-11-07 EP disclosed
US-6017888-A Stimulation of hair growth by peptide copper complexes PROCYTE CORPORATION (US) 2000-01-25 US disclosed
EP-0765152-A1 STIMULATION OF HAIR GROWTH BY PEPTIDE-COPPER COMPLEXES PROCYTE CORPORATION (US) 1997-04-02 EP disclosed
US-5538945-A Stimulation of hair growth by peptide copper complexes PROCYTE CORPORATION (US) 1996-07-23 US disclosed
WO-1995035085-A1 STIMULATION OF HAIR GROWTH BY PEPTIDE-COPPER COMPLEXES PROCYTE CORPORATION (US) 1995-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092836-A1 CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF CXCL10, CXCR3, CXCR6 SLC7A5 1763/4885CYP3A4 2636/4885ALPI 1986/4885
US-12565517-B2 Cyclic peptide having CTLA-4 inhibitory activity and use thereof CXCL10, MLX, MICA SLC7A5 1811/4885CYP3A4 2921/4885ALPI 1537/4885
US-20040142853-A1 Stimulation of hair growth by compositions containing peptide copper complexes and minoxidil PDGFA, FGF1, FGF2 SLC7A5 1616/4885CYP3A4 4276/4885ALPI 1911/4885
US-20100249042-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS CUTA, TYR, EYA3 SLC7A5 1624/4885CYP3A4 4834/4885ALPI 3945/4885
US-20040214749-A1 Compositions and methods for treatment of psoriasis TYR, CUTA, ETF1 SLC7A5 2905/4885CYP3A4 3746/4885ALPI 3338/4885
US-20040198639-A1 Preserved and stable compositions containing peptide copper complexes and methods related thereto AOC1, NONO, CUTA SLC7A5 2928/4885CYP3A4 3027/4885ALPI 3390/4885
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN RBP1, RBP4, SOD1 SLC7A5 1876/4885CYP3A4 4549/4885ALPI 2636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.